Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis

Source: Nasdaq GlobeNewswire / 05 Mar 2024 08:00:00   America/New_York